

MY TREATING HEALTHCARE PROVIDER CONTACT INFORMATION & DATE OF INFUSION

Name of treating healthcare provider:

Office phone:

After-hours phone:

My name and phone:

Date of YESCARTA® infusion:

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient has received YESCARTA®, which is an engineered autologous T-cell immunotherapy product that can lead to severe and even fatal cytokine release syndrome and neurologic adverse reactions. Cytokine release syndrome may involve any organ system. Other adverse reactions could include serious infections, febrile neutropenia, cytopenias, prolonged cytopenias and hypogammaglobulinemia.

- **WARNING:** Cytokine release syndrome and neurologic adverse reactions. See Prescribing Information for full details.

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (CONTINUED)

- Assess the patient for signs and symptoms of cytokine release syndrome, neurologic adverse reactions and infections.
- See the Healthcare Provider Educational Material on how to manage these events.
- **Contact the patient's physician immediately for further information.**



Patient Alert Card

The patient alert card is approved by the Ministry of Health as of MAY 2021.

Take this card with you if you go to the hospital or see any doctor other than your treating healthcare provider.

Be sure to tell all healthcare providers you see that you are being treated with YESCARTA® and SHOW THEM THIS CARD.

IMPORTANT REMINDERS FOR PATIENTS

- If you experience severe nausea, vomiting, diarrhoea, tiredness or any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare provider, or any healthcare provider available.
- Do not treat any of these symptoms with over-the-counter medications or herbal/dietary supplements without the approval of your treating healthcare provider.

IMPORTANT REMINDERS FOR PATIENTS (CONTINUED)

YESCARTA® can cause serious side effects in different parts of your body. These symptoms can be life threatening or even fatal and need to be addressed immediately.

Symptoms that appear mild may quickly worsen. Symptoms may be delayed and may occur weeks after your infusion.

Do not feel embarrassed or that you are inconveniencing your healthcare provider.

CALL YOUR TREATING HEALTHCARE PROVIDER RIGHT AWAY IF YOU HAVE ANY OF THESE SYMPTOMS

Neurologic Adverse Reactions

- Confusion
- Difficulty speaking
- Difficulty understanding speech
- Tremors (shaky arms or body parts)
- Agitation
- Increased sleepiness
- Dizziness

Cytokine Release Syndrome

- Fever (eg, temperature above 38°C)
- Tiredness

- Shortness of breath
- Low urine output
- Nausea
- Vomiting
- Diarrhoea
- Irregular heartbeat

Infections:

- Fever (eg, temperature above 38°C)
- Chills
- Sweating
- Pain
- Rash
- Tiredness
- Headache
- Cough
- Breathing Difficulties

Please see the YESCARTA® Prescribing Information, including the Patient Information Leaflet and the Healthcare Provider Educational Material, all of which can be obtained by contacting Kite, a Gilead Company, Medical Information at

medinfo.israel@gilead.com

You can report side effects to the Ministry of Health using the adverse event portal:

<https://sideeffects.health.gov.il>

or through the registration holder:

DrugSafety.Israel@gilead.com

YESCARTA, the YESCARTA Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.

© 2020 Kite Pharma, Inc. | KITE YES IL PAC: V1 12-11-2020

